501O_PR - Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC)
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Soft Tissue Sarcomas
Cancer Aetiology, Epidemiology, Prevention
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597|
R. Quek1, H.H. Loong2, V. Sriuranpong3, M. Farid1, S.H. Tan4, W.L. Goh1, S. Mingmalairak3, T.W. Chen5, C. Chang6, A. Pang7, S. Teo7, M.E. Puhaindran8, M.M. Maw9, R. Ngan10, A.K.C. Leung11, J.C. Chan11, T. Hirose12, M. Endo12, A. Kawai12
Angiosarcoma is an uncommon form of soft tissue sarcoma. Presentation and treatment are heterogeneous. We undertook a multicenter study evaluating the epidemiology, treatment and outcomes of AS pts in 8 sarcoma academic centres across Asia.
This is a retrospective chart review of AS pts seen at the study sites.
In total 423 pts were included into study. Median follow-up was 12.4 mths. 59% and 41% had cutaneous (C-AS) and visceral AS (V-AS) respectively. Median age was 67 yr [74 yr vs 54 yr in C-AS vs V-AS, p 3 lines of chemotherapy. The most common first line chemotherapy regimen was paclitaxel (54%) followed by liposomal doxorubicin (15%). In pts with localized AS who had undergone primary surgery, relapse-free survival was 10.9 mths, 12.9 vs 8.1 mths in pts with C-AS vs V-AS (HR 1.10, P = 0.6). Median overall survival (OS) was 23.7 mths, 24.0 mths in C-AS vs 23.0 mths in V-AS (HR 1.22, P = 0.3). In pts with locally advanced/metastatic AS, median OS on BSC was 1.7 mths vs 17.1 mths for those who received at least 1 line of chemotherapy (HR 5.30, P
This large observational study in AS is the first collaborative study by the ASC. This study highlights the complexity of AS and heterogeneity of treatment across Asia. Prognosis is poor and optimal treatment remains to be defined.
Clinical trial indentification
Legal entity responsible for the study
National Cancer Centre Singapore
R. Quek: Grants/research support: Novartis Pfizer, Janssen, Bayer and Eisai Honoraria or consultation fees: Novartis, Bayer, BMS, Merck, Roche, Eisai Participation in a company sponsored speaker’s bureau: Novartis, Bayer, Merck, Eisai. V. Sriuranpong: Corporate sponsored research: Novartis, MSD, Astra Zeneca, Roche, Lilly, Sanofi, Pfizer, BMS. All other authors have declared no conflicts of interest.